---
layout: archive
title: "Publications"
permalink: /publications/
author_profile: true
---

<sup>*</sup> indicates equal contributions.

## Refereed Journal Publications
1. Lin DY, Du Y, **Xu Y**, Paritala S, Donahue M, Maloney P. [Durability of XBB.1.5 Vaccines against Omicron Subvariants](https://www.nejm.org/doi/full/10.1056/NEJMc2402779). **New England Journal of Medicine**, 2024. \[[News](https://www.altmetric.com/details/163931419/news)\]
2. Lin DY<sup>*</sup>, **Xu Y**<sup>*</sup>, Gu Y, Sunny SK, Moore Z, Zeng D. [Impact of booster vaccination interval on SARS-CoV-2 infection, hospitalization, and death](https://www.ijidonline.com/article/S1201-9712(24)00155-3/fulltext). **International Journal of Infectious Diseases**, 2024.
3. **Xu Y**, Zeng D, Lin DY. [Proportional rates models for multivariate panel count data](https://academic.oup.com/biometrics/article/80/1/ujad011/7595108). **Biometrics**, 2024. [An earlier version of this manuscript won the **2023 ASA Lifetime Data Science (LiDS) Section Student Paper Award** and the **2024 ENAR Distinguished Student Paper Award**]
4. **Xu Y**, Zeng D, Lin DY. [Marginal proportional hazards models for multivariate interval-censored data](https://academic.oup.com/biomet/article-abstract/110/3/815/6794202). **Biometrika**, 2023.
5. Lin DY<sup>*</sup>, **Xu Y**<sup>*</sup>, Gu Y<sup>*</sup>, Zeng D, Wheeler B, Young H, Sunny SK, Moore Z. [Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on Omicron infection and severe outcomes in children under 12 years of age: an observational cohort study](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00272-4/fulltext). **The Lancet Infectious Diseases**, 2023. \[[News](https://www.altmetric.com/details/150195124/news?src=bookmarklet)\]
6. Lin DY, **Xu Y**, Gu Y, Zeng D, Sunny SK, Moore Z. [Durability of bivalent boosters against Omicron subvariants](https://www.nejm.org/doi/full/10.1056/NEJMc2302462). **New England Journal of Medicine**, 2023. \[[News](https://www.altmetric.com/details/145643558/news?src=bookmarklet)\]
7. Lin DY, **Xu Y**, Gu Y, Zeng D, Wheeler B, Young H, Sunny SK, Moore Z. [Effectiveness of bivalent boosters against severe Omicron infection](https://www.nejm.org/doi/full/10.1056/NEJMc2215471). **New England Journal of Medicine**, 2023. \[[News](https://www.altmetric.com/details/141787740/news?src=bookmarklet)\]
8. Paritala S, **Xu Y**, Du Y, Donahue M, Maloney P, Lin DY. [Effectiveness of Bivalent Boosters Over Nine and Half Months](https://www.fortunejournals.com/articles/effectiveness-of-bivalent-boosters-over-nine-and-half-months.html). **Journal of Biotechnology and Biomedicine**, 2023.
9. Lin DY, **Xu Y**, Zeng D, Sunny SK. [A Cost-Benefit Analysis of Bivalent Covid-19 Vaccines](https://www.fortunejournals.com/articles/a-costbenefit-analysis-of-bivalent-covid19-vaccines.html). **Journal of Biotechnology and Biomedicine**, 2023.
10. Lin DY, Gu Y, **Xu Y**, Wheeler B, Young H, Sunny SK, Moore Z, Zeng D. [Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes](https://jamanetwork.com/journals/jama/article-abstract/2796893). **JAMA**, 2022. \[[News](https://www.altmetric.com/details/136446237/news?src=bookmarklet)\]
11. Lin DY, Gu Y, **Xu Y**, Zeng D, Wheeler B, Young H, Sunny SK, Moore Z. [Effects of vaccination and previous infection on Omicron infections in children](https://www.nejm.org/doi/full/10.1056/NEJMc2209371). **New England Journal of Medicine**, 2022. \[[News](https://www.altmetric.com/details/135646402/news?src=bookmarklet)\]

## Under Review
1. **Xu Y**, Zeng D, Lin DY. Checking the Cox proportional hazards model with interval-censored data, 2024+.
2. Lin DY, Huang S, **Xu Y**, Milinovich A, Duggal A, Wang X. Waning effects of XBB.1.5 vaccines and antiviral drugs on severe outcomes of omicron infection in the USA, 2024+.

